Phoenix Bio

研究開発

研究開発

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes

    Tsuge, M. Hiraga, N. Zhang, Y. Yamashita, M.  Sato, O. Oka, N. Shiraishi, K. Izaki, Y. Makokha, G. N. Uchida, T. Kurihara, M. Nomura, M. Tsushima, K. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Fujita, T. Chayama, K.

    Virology. 2018 Sep 18;525:48-61. doi: 10.1016/j.virol.2018.08.020.

    CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

      Nomura, M. Tsuge, M. Uchida, T. Hiraga, N. Kurihara, M. Tsushima, K. Fujino, H. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Hiramatsu, A. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Zhang, Y. Makokha, G. N. Hayes, C. N. Tanaka, S. Chayama, K.

      J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.

      The metabolic fate of fenclozic acid in chimeric mice with a humanized liver

        Ekdahl, A. Weidolf, L. Baginski, M. Morikawa, Y. Thompson, R. A. Wilson, I. D.

        Arch Toxicol. 2018 Sep;92(9):2819-2828.

        Contribution of chimeric mice with a humanized liver to the evaluation of pharmacology, toxicity, and pharmacokinetics in drug discovery and development

          Sanoh, S. Ohta, S.

          Nihon Yakurigaku Zasshi. 2018;151(5):213-220

          Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

            Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

            J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

            Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

              Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

              Oncotarget. 2018 May 18;9(38):25075-25088.

              The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice

                de la Rosa Rodriguez, M. A. Sugahara, G. Hooiveld, Gjej Ishida, Y. Tateno, C. Kersten, S.

                BMC Genomics. 2018 Jun 7;19(1):443. doi: 10.1186/s12864-018-4834-3.

                Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

                  Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                  Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

                  Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions

                    Takaoka, N. Sanoh, S. Okuda, K. Kotake, Y. Sugahara, G. Yanagi, A. Ishida, Y. Tateno, C. Tayama, Y. Sugihara, K. Kitamura, S. Kurosaki, M. Terao, M. Garattini, E. Ohta, S.

                    Biochem Pharmacol. 2018 Apr 17;154:28-38.

                    FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver

                      Papazyan, R. Liu, X. Liu, J. Dong, B. Plummer, E. M. Lewis, R. D., 2nd Roth, J. D. Young, M. A.

                      J Lipid Res. 2018 Mar 20. pii: jlr.M081935. doi: 10.1194/jlr.M081935.

                      Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

                        Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

                        Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

                        Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

                          Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

                          J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

                          A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

                            Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

                            Antiviral Res. 2017 Dec 7;150:47-59.

                            Hepatitis C replication inhibitors that target the viral NS4B protein

                              Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

                              J Med Chem. 2014 Mar 13;57(5):2107-20

                              Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy

                                Sanoh, S. Tayama, Y. Sugihara, K. Kitamura, S. Ohta, S.

                                Drug Metab Pharmacokinet. 2015 Feb;30(1):52-63.

                                A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

                                  Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

                                  J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

                                  Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

                                    Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

                                    Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

                                    Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice

                                      Ohara A , Takahashi Y,  Kondo  M,  Okuda Y, Takeda  S,  Kushida M, Kobayashi  K,  Sumida K, Yamada T

                                      Toxicol Res. 2017; 6(6): 795-813

                                      Evaluation of the human relevance of the constitutive androstane receptor-mediated mode of action for rat hepatocellular tumor formation by the synthetic pyrethroid momfluorothrin

                                        Okuda, Y. Kushida, M. Kikumoto, H. Nakamura, Y. Higuchi, H. Kawamura, S. Cohen, S. M. Lake, B. G.Yamada, T.

                                        J Toxicol Sci. 2017;42(6):773-788. doi: 10.2131/jts.42.773.

                                        Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

                                          Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

                                          J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.